Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials

Richeldi, Luca; Cottin, Vincent; M. du Bois, Roland; Selman, Moisés; Kimura, Toshio; Bailes, Zelie; Schlenker‐Herceg, Rozsa; Stowasser, Susanne; M. Brown, Kevin

doi:10.1016/j.rmed.2016.02.001

Public

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials

Published in Respiratory Medicine • Feb 2, 2016

Authors:

Luca Richeldi

Vincent Cottin

Roland M. du Bois

Abstract

BACKGROUND AND PURPOSE: The Phase II TOMORROW trial and two Phase III INPULSIS(®) trials investigated the efficacy and safety of nintedanib versus placebo in patients with idiopathic pulmonary fibrosis (IPF). To obtain an overall estimate of the treatment effect of nintedanib 150 mg twice daily (bid...

Subject

Nintedanib

Medicine

Idiopathic pulmonary fibrosis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!